Literature DB >> 24139926

Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.

Yangmin Hu1, Leiqing Li, Wenlu Li, Huimin Xu, Ping He, Xiaofeng Yan, Haibin Dai.   

Abstract

The choice of antibiotic monotherapy or combination therapy to treat Pseudomonas aeruginosa bacteraemia is controversial. The aim of this review was to compare both types of therapy to determine which delivers the best outcome for P. aeruginosa bacteraemia. We systematically searched electronic bibliographic databases, including PubMed, Ovid EMBASE and The Cochrane Library, for clinical studies that compared combination therapy with monotherapy in the treatment of P. aeruginosa bacteraemia. Eligible articles were analysed using Stata(®)/SE software v.12.0. Stratification analysis was conducted by study design and treatment type. Publication bias was assessed using Begg's funnel plot and Egger's test. Ten studies (eight retrospective and two prospective) involving 1239 patients were analysed. We found no difference between combination therapy and monotherapy when the data were combined (odds ratio = 0.89, 95% confidence interval 0.57-1.40; P = 0.614) or when data were analysed in subgroups. Neither combination therapy nor monotherapy treatment appears to have a significant effect on mortality rates in patients with P. aeruginosa bacteraemia. Further studies evaluating the effects of combination therapy or monotherapy in more specialised cases, such as when encountering a multidrug-resistant organism, are necessary.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotic; Bacteraemia; Combination therapy; Monotherapy; Mortality; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2013        PMID: 24139926     DOI: 10.1016/j.ijantimicag.2013.09.002

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  17 in total

1.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

2.  Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines.

Authors: 
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

3.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

4.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

Review 5.  Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.

Authors:  Ilias Karaiskos; Helen Giamarellou
Journal:  Expert Opin Pharmacother       Date:  2014-04-28       Impact factor: 3.889

6.  Ecthyma gangrenosum, a skin manifestation of Pseudomonas aeruginosa sepsis in a previously healthy child: A case report.

Authors:  Stephanie Biscaye; Diane Demonchy; Mickael Afanetti; Audrey Dupont; Herve Haas; Antoine Tran
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Ecthyma gangrenosum: a report of eight cases.

Authors:  César Adrián Martínez-Longoria; Gloria María Rosales-Solis; Jorge Ocampo-Garza; Guillermo Antonio Guerrero-González; Jorge Ocampo-Candiani
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

8.  Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis.

Authors:  Nicholas S Britt; David J Ritchie; Marin H Kollef; C A Burnham; Michael J Durkin; Nicholas B Hampton; Scott T Micek
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies.

Authors:  Su Yu Tang; Shun Wen Zhang; Jiang Dong Wu; Fang Wu; Jie Zhang; Jiang Tao Dong; Peng Guo; Da Long Zhang; Jun Ting Yang; Wan Jiang Zhang
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

10.  Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  Nattawan Palavutitotai; Anupop Jitmuang; Sasima Tongsai; Pattarachai Kiratisin; Nasikarn Angkasekwinai
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.